title: Expression of PAX2 and PTEN Correlates to Therapy Response in Endometrial Hyperplasia.
abstract: OBJECTIVE
  To investigate if a levonorgestrel-impregnated intrauterine system (LNG-IUS) was more efficient compared to oral progestin in the clearance of the paired box 2 gene (PAX2) - and phosphatase and tensin homolog (PTEN)-null endometrial glands and assess the significance of PAX2- and PTEN-null glands as markers for therapy response in endometrial hyperplasia.
  
  
  METHODS
  Immunohistochemical staining using antibodies against PAX2 and PTEN was performed in 141 pre- and post-treatment endometrial biopsies comparing the effect of LNG-IUS, 10 mg medroxyprogesterone acetate (MPA) taken continuously, or 10 mg MPA taken 10 days per cycle for six months. PAX2- and PTEN-null glands were investigated by light microscopy in pre-and post-treatment biopsies.
  
  
  RESULTS
  Clearance of PAX2- and PTEN-null glands was significantly more efficient by LNG-IUS compared to oral MPA (p<0.000 and p=0.008, respectively) and significantly related to therapy response (p<0.000 and p=0.002, respectively).
authors.affiliation: Department of Clinical Pathology, University Hospital of Tromsø, Tromsø, Norway Research Group for Gynaecologic Oncology, Department of Medical Biology, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway anne.orbo@uit.no.
authors.forename: Anne
authors.initials: A
authors.lastname: Ørbo
authors.affiliation: Research Group for Gynaecologic Oncology, Department of Medical Biology, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway.
authors.forename: Marit
authors.initials: M
authors.lastname: Arnes
authors.affiliation: Department of Clinical Pathology, University Hospital of Tromsø, Tromsø, Norway.
authors.forename: Lena Myreng
authors.initials: LM
authors.lastname: Lyså
authors.affiliation: Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway.
authors.forename: Bjørn
authors.initials: B
authors.lastname: Straume
mesh_terms: D014408:Biomarkers, Tumor / Q000096:biosynthesis*; D004714:Endometrial Hyperplasia / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D007436:Intrauterine Devices, Medicated; D016912:Levonorgestrel / Q000008:administration & dosage*; D008875:Middle Aged; D051762:PAX2 Transcription Factor / Q000096:biosynthesis*; D051059:PTEN Phosphohydrolase / Q000096:biosynthesis*; D011372:Progestins / Q000008:administration & dosage*
chemical_list: D014408:Biomarkers, Tumor; D051762:PAX2 Transcription Factor; C497318:PAX2 protein, human; D011372:Progestins; D016912:Levonorgestrel; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human
keywords: Endometrial hyperplasia; PAX2; PTEN; progestin therapy; therapy response